Robert P. Baughman

Pulmonary Medicine

222 Piedmont Ave
Cincinnati, OH 45219

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 217 publications

Bridging the Gap: The Emerging Role of memory CD8+ T Cells in Fibrotic Interstitial Lung Disease.

Bridging the Gap: The Emerging Role of memory CD8+ T Cells in Fibrotic Interstitial Lung Disease.

Journal: American journal of respiratory cell and molecular biology

Published: March 18, 2026

Prevalence of relapse in pulmonary sarcoidosis: A systematic review and meta-analysis.

Prevalence of relapse in pulmonary sarcoidosis: A systematic review and meta-analysis.

Journal: Respiratory medicine

Published: March 03, 2026

Incidence of New Comorbidities After Steroid Use in Patients With Sarcoidosis: An International Cross-Sectional Survey.

Incidence of New Comorbidities After Steroid Use in Patients With Sarcoidosis: An International Cross-Sectional Survey.

Journal: Chest

Published: September 09, 2025

Incidence of New Comorbidities After Steroid Use in Patients With Sarcoidosis: An International Cross-Sectional Survey.

Incidence of New Comorbidities After Steroid Use in Patients With Sarcoidosis: An International Cross-Sectional Survey.

Journal: Chest

Published: September 09, 2025

Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): a randomised, double-blinded, multicentre, phase 2 study.

Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): a randomised, double-blinded, multicentre, phase 2 study.

Journal: The European respiratory journal

Published: September 04, 2025

Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): A randomized, double-blinded, multicenter, Phase 2 study.

Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): A randomized, double-blinded, multicenter, Phase 2 study.

Journal: The European respiratory journal

Published: September 04, 2025

WASOG Clinical Trial Endpoint Task Force: Executive Summary.

WASOG Clinical Trial Endpoint Task Force: Executive Summary.

Journal: Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG

Published: September 02, 2025

A paradigm shift in corticosteroid therapy for sarcoidosis: a World Association of Sarcoidosis and Other Granulomatous Disorders Position Paper, endorsed by the Americas Association of Sarcoidosis and Other Granulomatous Disorders.

A paradigm shift in corticosteroid therapy for sarcoidosis: a World Association of Sarcoidosis and Other Granulomatous Disorders Position Paper, endorsed by the Americas Association of Sarcoidosis and Other Granulomatous Disorders.

Journal: The Lancet. Respiratory medicine

Published: July 14, 2025

Methotrexate as Initial Therapy for Symptomatic Pulmonary Sarcoidosis?

Methotrexate as Initial Therapy for Symptomatic Pulmonary Sarcoidosis?

Journal: The New England journal of medicine

Published: May 19, 2025

Pulmonary sarcoidosis clinical trial end-points: a Delphi study.

Pulmonary sarcoidosis clinical trial end-points: a Delphi study.

Journal: The European respiratory journal

Published: May 07, 2025

Airway involvement in pulmonary sarcoidosis: Clinical and CT features.

Airway involvement in pulmonary sarcoidosis: Clinical and CT features.

Journal: Respiratory medicine

Published: March 29, 2025

Design of RESOLVE Lung, a multinational Phase 2, randomized, placebo-controlled trial of the anti-GM-CSF monoclonal antibody namilumab in patients with chronic pulmonary sarcoidosis.

Design of RESOLVE Lung, a multinational Phase 2, randomized, placebo-controlled trial of the anti-GM-CSF monoclonal antibody namilumab in patients with chronic pulmonary sarcoidosis.

Journal: Contemporary clinical trials

Published: March 03, 2025

Showing 1-12 of 217

Last Updated: 09/26/2026